Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin Lymphoma

NCT05201248 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT05201248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05201248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin Lymphoma
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 10, 2022
Completion date
September 30, 2026
Enrollment
49 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma